MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01DA5860.84644740"

Данный документ является веб-страницей в одном файле, также называемой файлом веб-архива. Если вы видите это сообщение, значит, данный браузер или редактор не поддерживает файлы веб-архива. Загрузите браузер, поддерживающий веб-архивы, например Windows® Internet Explorer®.

------=_NextPart_01DA5860.84644740
Content-Location: file:///C:/680C1E39/UA61760101_6F09.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link rel=3DFile-List href=3D"UA61760101_6F09.files/filelist.xml">
<link rel=3DPreview href=3D"UA61760101_6F09.files/preview.wmf">
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>solesnaya</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Bravada</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>1</o:TotalTime>
  <o:LastPrinted>2017-02-09T09:50:00Z</o:LastPrinted>
  <o:Created>2024-02-05T16:24:00Z</o:Created>
  <o:LastSaved>2024-02-05T16:24:00Z</o:LastSaved>
  <o:Pages>5</o:Pages>
  <o:Words>2080</o:Words>
  <o:Characters>11860</o:Characters>
  <o:Company>USN Team</o:Company>
  <o:Lines>98</o:Lines>
  <o:Paragraphs>27</o:Paragraphs>
  <o:CharactersWithSpaces>13913</o:CharactersWithSpaces>
  <o:Version>14.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=3DdataStoreItem href=3D"UA61760101_6F09.files/item0001.xml"
target=3D"UA61760101_6F09.files/props002.xml">
<link rel=3DthemeData href=3D"UA61760101_6F09.files/themedata.thmx">
<link rel=3DcolorSchemeMapping href=3D"UA61760101_6F09.files/colorschememap=
ping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:DrawingGridHorizontalSpacing>5,5 пт</w:DrawingGridHorizontalSpacing>
  <w:DisplayHorizontalDrawingGridEvery>2</w:DisplayHorizontalDrawingGridEve=
ry>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>RU</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:DontUseIndentAsNumberingTabStop/>
   <w:FELineBreak11/>
   <w:WW11IndentRules/>
   <w:DontAutofitConstrainedTables/>
   <w:AutofitLikeWW11/>
   <w:HangulWidthLikeWW11/>
   <w:UseNormalStyleForList/>
   <w:DontVertAlignCellWithSp/>
   <w:DontBreakConstrainedForcedTables/>
   <w:DontVertAlignInTxbx/>
   <w:Word11KerningPairs/>
   <w:CachedColBalance/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val=3D"Cambria Math"/>
   <m:brkBin m:val=3D"before"/>
   <m:brkBinSub m:val=3D"&#45;-"/>
   <m:smallFrac m:val=3D"off"/>
   <m:dispDef/>
   <m:lMargin m:val=3D"0"/>
   <m:rMargin m:val=3D"0"/>
   <m:defJc m:val=3D"centerGroup"/>
   <m:wrapIndent m:val=3D"1440"/>
   <m:intLim m:val=3D"subSup"/>
   <m:naryLim m:val=3D"undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" DefUnhideWhenUsed=3D"true"
  DefSemiHidden=3D"true" DefQFormat=3D"false" DefPriority=3D"99"
  LatentStyleCount=3D"267">
  <w:LsdException Locked=3D"false" Priority=3D"0" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Normal"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"heading 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"35" QFormat=3D"true" Name=3D=
"caption"/>
  <w:LsdException Locked=3D"false" Priority=3D"10" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" Name=3D"Default Paragraph=
 Font"/>
  <w:LsdException Locked=3D"false" Priority=3D"11" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtitle"/>
  <w:LsdException Locked=3D"false" Priority=3D"22" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Strong"/>
  <w:LsdException Locked=3D"false" Priority=3D"20" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"59" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Table Grid"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Placeho=
lder Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"No Spacing"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Revisio=
n"/>
  <w:LsdException Locked=3D"false" Priority=3D"34" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"List Paragraph"/>
  <w:LsdException Locked=3D"false" Priority=3D"29" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"30" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"19" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"21" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"31" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"32" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"33" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Book Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"37" Name=3D"Bibliography"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" QFormat=3D"true" Name=3D=
"TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520092929 1073786111 9 0 415 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520081665 -1073717157 41 0 66047 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-priority:99;
	mso-style-link:"Верхний колонтитул Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 233.85pt right 467.75pt;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-priority:99;
	mso-style-link:"Нижний колонтитул Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 233.85pt right 467.75pt;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Текст выноски Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:"Tahoma","sans-serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:none;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParag=
raphCxSpFirst
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:none;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListPar=
agraphCxSpMiddle
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:none;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagra=
phCxSpLast
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:none;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
span.a
	{mso-style-name:"Текст выноски Знак";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Текст выноски";
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;
	font-family:"Tahoma","sans-serif";
	mso-ascii-font-family:Tahoma;
	mso-hansi-font-family:Tahoma;
	mso-bidi-font-family:Tahoma;}
span.a0
	{mso-style-name:"Верхний колонтитул Знак";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Верхний колонтитул";}
span.a1
	{mso-style-name:"Нижний колонтитул Знак";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Нижний колонтитул";}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	mso-ascii-font-family:Calibri;
	mso-hansi-font-family:Calibri;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("UA61760101_6F09.files/header.htm") fs;
	mso-footnote-continuation-separator:url("UA61760101_6F09.files/header.htm"=
) fcs;
	mso-endnote-separator:url("UA61760101_6F09.files/header.htm") es;
	mso-endnote-continuation-separator:url("UA61760101_6F09.files/header.htm")=
 ecs;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:2.0cm 1.0cm 2.0cm 3.0cm;
	mso-header-margin:35.45pt;
	mso-footer-margin:35.45pt;
	mso-title-page:yes;
	mso-footer:url("UA61760101_6F09.files/header.htm") f1;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:-2;
	mso-list-type:simple;
	mso-list-template-ids:2047257822;}
@list l0:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:*;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:0cm;
	text-indent:0cm;}
@list l1
	{mso-list-id:196360738;
	mso-list-type:hybrid;
	mso-list-template-ids:432861792 420376268 68747267 68747269 68747265 68747=
267 68747269 68747265 68747267 68747269;}
@list l1:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:–;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
@list l1:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2
	{mso-list-id:233857882;
	mso-list-type:hybrid;
	mso-list-template-ids:-1607806318 2047257822 68747267 68747269 68747265 68=
747267 68747269 68747265 68747267 68747269;}
@list l2:level1
	{mso-level-start-at:65535;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:40.7pt;
	text-indent:-18.0pt;
	font-family:"Times New Roman","serif";}
@list l2:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:76.7pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l2:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:112.7pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:148.7pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l2:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:184.7pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l2:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:220.7pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:256.7pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l2:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:292.7pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l2:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:328.7pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l0:level1 lfo2
	{mso-level-start-at:65535;
	mso-level-numbering:continue;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Times New Roman","serif";}
@list l0:level1 lfo3
	{mso-level-start-at:65535;
	mso-level-numbering:continue;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:9.35pt;
	mso-level-legacy-space:0cm;
	margin-left:0cm;
	text-indent:0cm;
	font-family:"Times New Roman","serif";}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Обычная таблица";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DRU style=3D'tab-interval:35.45pt'>

<div class=3DWordSection1>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:194.75pt;margin-bottom:.0001pt;line-height:normal;background:wh=
ite'><b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>ІНСТРУКЦІЯ</span></b><span lang=3DUK style=3D'font-fa=
mily:
"Times New Roman","serif";mso-ansi-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-top:0cm;margin-right:9.=
0pt;
margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center;
line-height:normal;background:white'><b><span lang=3DUK style=3D'font-size:=
12.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>для медичного
застосування лікарського засобу<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-top:0cm;margin-right:9.=
0pt;
margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center;
line-height:normal;background:white'><span lang=3DUK style=3D'font-family:"=
Times New Roman","serif";
mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-top:0cm;margin-right:19=
8.4pt;
margin-bottom:0cm;margin-left:194.75pt;margin-bottom:.0001pt;text-align:cen=
ter;
line-height:normal;background:white'><b><span lang=3DUK style=3D'font-size:=
12.0pt;
font-family:"Times New Roman","serif";letter-spacing:-.15pt;mso-ansi-langua=
ge:
UK'>АРКУРОН </span></b><b><span lang=3DUK style=3D'font-size:12.0pt;font-fa=
mily:
"Times New Roman","serif";letter-spacing:-.2pt;mso-ansi-language:UK'>(</spa=
n></b><b><span
lang=3DEN-US style=3D'font-size:12.0pt;font-family:"Times New Roman","serif=
";
letter-spacing:-.2pt;mso-ansi-language:EN-US'>ARCURON</span></b><b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
letter-spacing:-.2pt;mso-ansi-language:UK'>)<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:198.4pt;margin-bo=
ttom:
0cm;margin-left:194.75pt;margin-bottom:.0001pt;line-height:normal;backgroun=
d:
white'><b><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New =
Roman","serif";
letter-spacing:-.2pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.7pt;margin-bottom:.0001pt;text-align:justify;line-height:norma=
l;
background:white'><b style=3D'mso-bidi-font-weight:normal'><i><span lang=3D=
UK
style=3D'font-size:13.0pt;font-family:"Times New Roman","serif";letter-spac=
ing:
-.6pt;mso-ansi-language:UK'>Склад:</span></i></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-=
ansi-language:
UK'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:151.2pt;margin-bo=
ttom:
0cm;margin-left:.35pt;margin-bottom:.0001pt;text-align:justify;line-height:
normal;background:white'><i><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-ansi-language:UK'>діюча речовина: </span></i>=
<span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>1 ампула містить піпекуронію броміду 4 мг; <i>допоміж=
на
речовина: </i>маніт (Е 421).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:151.2pt;margin-bo=
ttom:
0cm;margin-left:.35pt;margin-bottom:.0001pt;text-align:justify;line-height:
normal;background:white'><span lang=3DUK style=3D'font-size:8.0pt;font-fami=
ly:"Times New Roman","serif";
mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.7pt;margin-bottom:.0001pt;text-align:justify;line-height:norma=
l;
background:white'><b><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-ansi-language:UK'>Лікарська форма. </span></b><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>Ліофілізат для розчину для ін'єкцій.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK;mso-bidi-font-weight:bold'>Основні фізико-хімічні
властивості:<b> </b></span></i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>ліофілізований
порошок білого або майже білого</span><span lang=3DUK style=3D'font-family:=
"Times New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";letter-spacing:-.25pt;mso-ansi-language:UK'>кольо=
ру.</span><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.7pt;margin-bottom:.0001pt;text-align:justify;line-height:norma=
l;
background:white'><span lang=3DUK style=3D'font-size:8.0pt;font-family:"Tim=
es New Roman","serif";
mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:43.2pt;margin-bot=
tom:
0cm;margin-left:1.8pt;margin-bottom:.0001pt;text-align:justify;line-height:
normal;background:white'><b><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";letter-spacing:-.05pt;mso-ansi-language:UK'>Фарма=
котерапевтична
група. </span></b><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Ti=
mes New Roman","serif";
letter-spacing:-.05pt;mso-ansi-language:UK'>Міорелаксанти з периферичним
механізмом дії. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:43.2pt;margin-bot=
tom:
0cm;margin-left:1.8pt;margin-bottom:.0001pt;text-align:justify;line-height:
normal;background:white'><span lang=3DUK style=3D'font-size:12.0pt;font-fam=
ily:
"Times New Roman","serif";mso-ansi-language:UK'>Код АТХ М03А С06.<o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:8.0=
pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p>&nbsp;</o:=
p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>Фармакологічні
властивості</span></i></b><b><span lang=3DUK style=3D'font-size:12.0pt;font=
-family:
"Times New Roman","serif";mso-ansi-language:UK'>.</span></b><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
letter-spacing:-.15pt;mso-ansi-language:UK'>Фармакодинаміка.</span></i><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Піпекуронію бромід є недеполяризуючим нервово-м'язовим
блокатором тривалої дії. За</span><span lang=3DUK style=3D'font-family:"Tim=
es New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>рахунок компетитивного зв'я=
зку
з нікотин-чутливими рецепторами ацетилхоліну,</span><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'> </spa=
n><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>розташованими у моторних закінченнях поперечносмугаст=
их
м'язових волокон, блокує</span><span lang=3DUK style=3D'font-family:"Times =
New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>передачу сигналу від нервов=
их
закінчень до м'язових волокон. Його антидотами є</span><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'> </spa=
n><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>інгібітори ацетилхолінестерази (наприклад неостигмін,
піридостигмін, едрофоній). На</span><span lang=3DUK style=3D'font-family:"T=
imes New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>відміну від деполяризуючих
міорелаксантів (наприклад сукцинілхолін), піпекуронію</span><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'> </spa=
n><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>бромід не спричиняє м'язової фасцикуляції. Піпекуронію
бромід не чинить гормональної</span><span lang=3DUK style=3D'font-family:"T=
imes New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";letter-spacing:-.25pt;mso-ansi-language:UK'>дії.<=
/span><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Навіть у дозах, що у кілька разів перевищують його
ефективну дозу, необхідну для 90 %</span><span lang=3DUK style=3D'font-fami=
ly:"Times New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>зниження м'язової
контрактильності (</span><span lang=3DEN-US style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-ansi-language:EN-US'>ED</span><sub><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>90</span></sub><span lang=3DUK style=3D'font-size:12.0pt;font-family:"T=
imes New Roman","serif";
mso-ansi-language:UK'>), не має гангліоблокуючої, ваголітичної та</span><sp=
an
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'> </span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>симпатоміметичної активності.</span><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>За даними досліджень, при збалансованій анестезії доз=
и </span><span
lang=3DEN-US style=3D'font-size:12.0pt;font-family:"Times New Roman","serif=
";
mso-ansi-language:EN-US'>ED</span><sub><span lang=3DUK style=3D'font-size:1=
2.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>50</span></sub>=
<span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'> і </span><span lang=3DEN-US style=3D'font-size:12.0p=
t;
font-family:"Times New Roman","serif";mso-ansi-language:EN-US'>ED</span><su=
b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>90</span></sub><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'> піпекуронію
броміду</span><span lang=3DUK style=3D'font-family:"Times New Roman","serif=
";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>становлять 0,03 і 0,05 мг/кг
маси тіла відповідно.</span><span lang=3DUK style=3D'font-family:"Times New=
 Roman","serif";
mso-ansi-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm'><span lang=3DUK style=3D'font-siz=
e:12.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>Доза, що станов=
ить
0,05 мг/кг маси тіла, забезпечує 40-50-хвилинну м'язову релаксацію</span><s=
pan
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'> </span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>під час різних операцій.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Максимальна дія піпекуронію броміду залежить від дози=
 і
настає через 1,5-5&nbsp;хвилин. Ефект розвивається швидше за все при дозах,=
 що
становлять 0,07-0,08 <span style=3D'mso-bidi-font-weight:bold'>мг/кг<b> </b=
></span>маси
тіла. Подальше збільшення дози скорочує час, необхідний для розвитку дії, т=
а <span
style=3D'mso-bidi-font-weight:bold'>істотно </span>подовжує дію препарату. =
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Фармакокінетика.</span></i><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>При внутрішньовенному введенні початковий об'єм розпо=
ділу
(</span><span lang=3DEN-US style=3D'font-size:12.0pt;font-family:"Times New=
 Roman","serif";
mso-ansi-language:EN-US'>Vd<sub>c</sub></span><span lang=3DUK style=3D'font=
-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:UK'>) станов=
ить:
110 мл/кг маси тіла; об'єм розподілу у фазі насичення (</span><span lang=3D=
EN-US
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
EN-US'>Vd<sub>ss</sub></span><span lang=3DUK style=3D'font-size:12.0pt;font=
-family:
"Times New Roman","serif";mso-ansi-language:UK'>) – 300 ± 78 мл/кг; плазмов=
ий
кліренс (СІ) – 2,4 <i>± </i>0,5 мл/хв/кг; середній час напіввиведення <span
style=3D'mso-bidi-font-style:italic'>(</span></span><span lang=3DEN-US
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
EN-US;mso-bidi-font-style:italic'>t</span><sub><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:UK;mso-bidi-=
font-style:
italic'>1/2</span></sub><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-ansi-language:UK;mso-bidi-font-style:italic'>)<i> </i>–</span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'> 121 ± 45 хвилин; середній час присутності (</span><s=
pan
lang=3DEN-US style=3D'font-size:12.0pt;font-family:"Times New Roman","serif=
";
mso-ansi-language:EN-US'>MRT</span><span lang=3DUK style=3D'font-size:12.0p=
t;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>) – 140 хвилин.=
<i><o:p></o:p></i></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>При повторному введенні підтримуючих доз кумулятивний
ефект <span style=3D'mso-bidi-font-weight:bold'>несуттєвий<b>, </b></span>я=
кщо у
момент відновлення 25 % початкової контрактильності застосовані дози 0,01-0=
,02
мг/кг. <br>
75 % препарату виводиться у незмінному стані переважно нирками, 56 % за пер=
ші
24&nbsp;години, а інша кількість – у формі 3-дезацетил-піпекуронію. Печінка
також бере участь в елімінації піпекуронію.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:8.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:324.0pt;margin-bo=
ttom:
0cm;margin-left:2.15pt;margin-bottom:.0001pt;line-height:normal;background:
white'><b><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New =
Roman","serif";
letter-spacing:-.1pt;mso-ansi-language:UK'>Клінічні характеристики. </span>=
</b><b><i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Показання.</span></i></b><span lang=3DUK style=3D'fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:6.5pt;margin-bott=
om:0cm;
margin-left:2.9pt;margin-bottom:.0001pt;text-align:justify;line-height:norm=
al;
background:white'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Ti=
mes New Roman","serif";
mso-ansi-language:UK'>Міорелаксація на тлі загальної анестезії для полегшен=
ня
ендотрахеальної інтубації та проведення хірургічних втручань, що вимагають =
більш
ніж 20-30-хвилинну міорелаксацію.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:6.5pt;margin-bott=
om:0cm;
margin-left:2.9pt;margin-bottom:.0001pt;text-align:justify;line-height:norm=
al;
background:white'><span lang=3DUK style=3D'font-size:8.0pt;font-family:"Tim=
es New Roman","serif";
mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:nor=
mal;
background:white'><b><i><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
letter-spacing:-.1pt;mso-ansi-language:UK'>Протипоказання.</span></i></b><s=
pan
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:6.85pt;margin-bot=
tom:
0cm;margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:
normal;background:white'><span lang=3DUK style=3D'font-size:12.0pt;font-fam=
ily:
"Times New Roman","serif";mso-ansi-language:UK'>Відома підвищена чутливість=
 до діючої
речовини препарату (до піпекуронію або до брому) або до допоміжної речовини.
Міастенія.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:6.85pt;margin-bot=
tom:
0cm;margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:
normal;background:white'><span lang=3DUK style=3D'font-size:8.0pt;font-fami=
ly:"Times New Roman","serif";
mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:13.=
3pt;
mso-line-height-rule:exactly;background:white'><b><i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>Взаємодія </span></i></b><b style=3D'mso-bidi-font-weight:normal'><i><s=
pan
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>з</span></i></b><i><span lang=3DUK style=3D'font-size=
:12.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'> <b>іншими
лікарськими засобами та інші </b><b style=3D'mso-bidi-font-weight:normal'>в=
иди
взаємодій.</b></span></i><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p><=
/o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:13.=
3pt;
mso-line-height-rule:exactly;background:white'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:UK'>Лікарськ=
і препарати,
наведені нижче, здатні впливати на Аркурон.</span><span style=3D'font-famil=
y:
"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:13.=
3pt;
mso-line-height-rule:exactly;tab-stops:14.05pt;background:white'><i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
letter-spacing:-1.5pt;mso-ansi-language:UK'>1.</span></i><i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'><span style=3D'mso-tab-count:1'>  </span>Посилюють або подовжують дію:<=
/span></i><span
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:1.1pt;margin-right:0cm;margin-bott=
om:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:13.=
7pt;
mso-line-height-rule:exactly;tab-stops:12.25pt;background:white'><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>–&nbsp;інгаляційні анестетики (галотан, метоксифлуран, диетиловий ефір,
енфлуран, ізофлуран, циклопропан);<i><o:p></o:p></i></span></p>

<p class=3DMsoNormal style=3D'margin-top:.7pt;margin-right:0cm;margin-botto=
m:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:14.=
05pt;
mso-line-height-rule:exactly;tab-stops:12.25pt;background:white'><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>–</span><span lang=3DUK style=3D'font-family:"Times New Roman","serif";
mso-ansi-language:UK'>&nbsp;</span><span lang=3DUK style=3D'font-size:12.0p=
t;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>анестезуючі зас=
оби
для внутрішньовенного введення (кетамін, фентаніл, пропанідид, барбітурати,
етомідат, </span><span style=3D'font-size:12.0pt;mso-bidi-font-size:11.0pt;
font-family:"Times New Roman","serif"'>&#947;</span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>-гідроксимасляна кислота);<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:.35pt;margin-right:0cm;margin-bott=
om:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:14.=
05pt;
mso-line-height-rule:exactly;tab-stops:12.25pt;background:white'><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>–&nbsp;інші недеполяризуючі міорелаксанти, попереднє застосування
сукцинілхоліну;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:14.=
05pt;
mso-line-height-rule:exactly;tab-stops:12.25pt;background:white'><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>–&nbsp;деякі антибіотики і хіміотерапевтичні препарати (аміноглікозиди,
поліпептиди, імідазоли, метронідазол);<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:14.=
05pt;
mso-line-height-rule:exactly;background:white'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:UK'>–&nbsp;д=
іуретики,
</span><span style=3D'font-size:12.0pt;mso-bidi-font-size:11.0pt;font-famil=
y:
"Times New Roman","serif"'>&#945;</span><span lang=3DUK style=3D'font-size:=
12.0pt;
mso-bidi-font-size:11.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>- і </span><span style=3D'font-size:12.0pt;mso-bidi-font-size:11.0pt;
font-family:"Times New Roman","serif"'>&#946;</span><span lang=3DUK
style=3D'font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New =
Roman","serif";
mso-ansi-language:UK'>-</span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>блокатори, тіамін, інгібіто=
ри
МАО, гуанідин, протамін, фенітоїн, антагоністи кальцієвих каналів, солі маг=
нію,
лідокаїн для внутрішньовенного введення.</span><span lang=3DUK style=3D'fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:14.=
05pt;
mso-line-height-rule:exactly;tab-stops:14.05pt;background:white'><i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
letter-spacing:-1.1pt;mso-ansi-language:UK'>2.</span></i><i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'><span style=3D'mso-tab-count:1'> </span><span style=3D'letter-spacing:-=
.05pt'>Послаблюють
дію: </span></span></i><span lang=3DUK style=3D'font-family:"Times New Roma=
n","serif";
mso-ansi-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:1.1pt;margin-right:0cm;margin-bott=
om:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:13.=
7pt;
mso-line-height-rule:exactly;background:white'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:UK'>–&nbsp;т=
ривале
попереднє застосування глюкокортикостероїдів, неостигміну, едрофонію,
піридостигміну, норадреналіну, азатіоприну, теофіліну, калію хлориду, натрію
хлориду, кальцію хлориду.</span><span lang=3DUK style=3D'font-family:"Times=
 New Roman","serif";
mso-ansi-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:13.=
7pt;
mso-line-height-rule:exactly;tab-stops:17.3pt;background:white'><i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
letter-spacing:-1.15pt;mso-ansi-language:UK'>3.</span></i><i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'><span style=3D'mso-tab-count:1'>   </span>Посилюють або послаблюють дію=
:</span></i><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:.35pt;margin-right:0cm;margin-bott=
om:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:13.=
7pt;
mso-line-height-rule:exactly;tab-stops:15.5pt;background:white'><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>–<i>&nbsp;</i>попереднє застосування деполяризуючих міорелаксантів (зал=
ежно
від дози, тривалості застосування та індивідуальної чутливості пацієнта).<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><b
style=3D'mso-bidi-font-weight:normal'><i><span lang=3DUK style=3D'font-size=
:8.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p>&nbsp;</o:=
p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><b
style=3D'mso-bidi-font-weight:normal'><i><span lang=3DUK style=3D'font-size=
:12.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>Особливості
застосування.</span></i></b><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Аркурон слід застосовувати винятково в умовах
спеціалізованого стаціонару у</span><span lang=3DUK style=3D'font-family:"T=
imes New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>присутності досвідченого лі=
каря
та при наявності апаратури для проведення</span><span lang=3DUK style=3D'fo=
nt-family:
"Times New Roman","serif";mso-ansi-language:UK'> </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>ендотрахеальної інтубації, штучної вентиляції легенів, кисневої терапії=
 і
препаратів-<span style=3D'letter-spacing:-.15pt'>антагоністів.</span></span=
><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>У медичній літературі описані випадки анафілактичної =
та
анафілактоїдної реакцій при</span><span lang=3DUK style=3D'font-family:"Tim=
es New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>застосуванні міорелаксантів=
. Анафілактичні
та анафілактоїдні реакції іноді можуть зустрічатися при застосуванні
недеполяризуючих міорелаксантів. Незважаючи на відсутність повідомлень про
подібну дію</span><span lang=3DUK style=3D'font-family:"Times New Roman","s=
erif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>Аркурону, препарат слід
застосовувати винятково в умовах, що дозволяють негайно</span><span lang=3D=
UK
style=3D'font-family:"Times New Roman","serif"'> </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>приступити до лікування таких станів. Препарат слід застосовувати з
особливою обережністю при наявності в анамнезі алергічної реакції до інших
міорелаксантів, оскільки між недеполяризуючими міорелаксантами може
сформуватися перехресна алергія.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Вивільнення гістаміну і подібні до гістаміну реакції:
піпекуронію бромід не вивільняє гістамін. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Піпекуронію бромід має легкий гемодинамічний ефект,
можливо, через його слабко виражений кардіоселективний, ваголітичний ефект.=
 При
застосуванні дози до 0,1 мг/кг маси тіла не відзначали гангліоблокуючої або
ваголітичної дії, тільки слабко виражені серцево-судинні побічні ефекти
(зниження артеріального тиску, брадикардія), особливо при одночасному
застосуванні галотану або фентанілу під час введення наркозу.<o:p></o:p></s=
pan></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Дози Аркурону, що спричиняють міорелаксацію, не мають
істотного кардіоваскулярного</span><span lang=3DUK style=3D'font-family:"Ti=
mes New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>ефекту і, на відміну від де=
яких
анестетиків, практично не спричиняють брадикардію,</span><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'> </spa=
n><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>зумовлену вагусним рефлексом.</span><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>З огляду на вищезазначене застосування і дозування
ваголітичних препаратів з метою</span><span lang=3DUK style=3D'font-family:=
"Times New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>премедикації підлягає ретел=
ьній
попередній оцінці; слід також врахувати стимулюючий</span><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'> </spa=
n><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>вплив на вагус інших лікарських засобів, що застосову=
ють
одночасно, і тип операції.</span><span lang=3DUK style=3D'font-family:"Time=
s New Roman","serif";
mso-ansi-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>З метою запобігання відносному передозуванню препарат=
у і
забезпечення відповідного</span><span lang=3DUK style=3D'font-family:"Times=
 New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>контролю за відновленням
м'язової активності рекомендується застосовувати стимулятор</span><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'> </span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
letter-spacing:-.1pt;mso-ansi-language:UK'>периферичних нервів.</span><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Необхідно з особливою обережністю вводити препарат
пацієнтам з алергією на інші</span><span lang=3DUK style=3D'font-family:"Ti=
mes New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>міорелаксанти в анамнезі че=
рез
можливу перехресну алергію.</span><span lang=3DUK style=3D'font-family:"Tim=
es New Roman","serif";
mso-ansi-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:.7pt;margin-right:0cm;margin-botto=
m:0cm;
margin-left:0cm;margin-bottom:.0001pt;text-align:justify;background:white'>=
<u><span
lang=3DUK style=3D'font-size:12.0pt;line-height:115%;font-family:"Times New=
 Roman","serif";
mso-ansi-language:UK'>На фармакокінетику і/або міорелаксуючий ефект Аркурону
можуть впливати наступні</span></u><span lang=3DUK style=3D'font-family:"Ti=
mes New Roman","serif"'>
</span><u><span lang=3DUK style=3D'font-size:12.0pt;line-height:115%;font-f=
amily:
"Times New Roman","serif";letter-spacing:-.2pt;mso-ansi-language:UK'>фактор=
и:</span></u><span
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>Ниркова недоста=
тність</span></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'> подовжує дію і час так званого «повернення» хворого.=
</span><span
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>Нервово-м'язові
захворювання:</span></i><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-ansi-language:UK'> Аркурон призначати з обережністю через можливе у</sp=
an><span
lang=3DUK style=3D'font-family:"Times New Roman","serif"'> </span><span lan=
g=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>таких випадках як посилення, так і послаблення дії препарату.</span><sp=
an
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>Захворювання
печінки:</span></i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"T=
imes New Roman","serif";
mso-ansi-language:UK'> застосування Аркурону можливе лише у випадках, коли
очікувана</span><span lang=3DUK style=3D'font-family:"Times New Roman","ser=
if"'> </span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>користь перевищує можливий негативний вилив.</span><s=
pan
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>Злоякісна
гіпертермія:</span></i><span lang=3DUK style=3D'font-size:12.0pt;font-famil=
y:"Times New Roman","serif";
mso-ansi-language:UK'> ні у ході досліджень Аркурону, ні у клінічній практи=
ці
злоякісну</span><span lang=3DUK style=3D'font-family:"Times New Roman","ser=
if"'> </span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>гіпертермію не спостерігали. У зв'язку з тим, що
міорелаксант ніколи не застосовують без</span><span lang=3DUK style=3D'font=
-family:
"Times New Roman","serif";mso-ansi-language:UK'> </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>інших лікарських засобів, а також оскільки цей синдром може розвинутися=
 і за
відсутності</span><span lang=3DUK style=3D'font-family:"Times New Roman","s=
erif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>відомих провокуючих факторі=
в,
лікар має знати, які бувають ранні ознаки синдрому,</span><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'> </spa=
n><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>методи його діагностики і лікування.</span><span lang=
=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Інше: </span></i><span lang=3DUK style=3D'font-size:1=
2.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>перед початком
анестезії необхідно компенсувати наявні водно-електролітні</span><span lang=
=3DUK
style=3D'font-family:"Times New Roman","serif"'> </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>розлади і порушення рН крові.</span><span style=3D'font-family:"Times N=
ew Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm'><span lang=3DUK style=3D'font-siz=
e:12.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>Гіпотермія може
пролонгувати дію препарату.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.3pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Гіпокаліємія, дигіталізація, прийом діуретиків, гіпер=
магніємія,
гіпокальціємія</span><span lang=3DUK style=3D'font-family:"Times New Roman"=
,"serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>(трансфузія), дегідратація,=
 ацидоз,
гіпопротеїнемія, гіперкапнія, кахексія можуть сприяти</span><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'> </spa=
n><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>посиленню і подовженню дії Аркурону.</span><span lang=
=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:.35pt;margin-right:0cm;margin-bott=
om:0cm;
margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:13.3pt;
mso-line-height-rule:exactly;background:white'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:UK'>У пацієн=
тів
із серцево-судинними захворюваннями, набряками, а також в осіб літнього вік=
у, у
яких зменшена швидкість циркуляції крові, дія препарату може починатися <sp=
an
style=3D'letter-spacing:-.05pt'>пізніше, ніж зазвичай.</span></span><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.3pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Подібно до інших міорелаксантів Аркурон може частково
знижувати тромбопластиновий <span style=3D'letter-spacing:-.05pt'>і
протромбіновий час.</span></span><span style=3D'font-family:"Times New Roma=
n","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.3pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Необхідно застосовувати лише свіжоприготовлений розчи=
н.</span><span
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:13.=
7pt;
mso-line-height-rule:exactly;tab-stops:15.5pt;background:white'><span lang=
=3DUK
style=3D'font-size:8.0pt;font-family:"Times New Roman","serif";mso-ansi-lan=
guage:
UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.3pt;mso-line-height-rule:exactly;tab-stops:423.7pt;
background:white'><i><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-ansi-language:UK'>Застосування у період вагітності або годування груддю=
.</span></i><i
style=3D'mso-bidi-font-style:normal'><span style=3D'font-family:"Times New =
Roman","serif"'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.3pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>Дані, достатні для доказу нешкідливості Аркурону для
вагітних або плода, відсутні.</span><span lang=3DUK style=3D'font-family:"T=
imes New Roman","serif"'>
</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Rom=
an","serif";
mso-ansi-language:UK'>Невідомо, чи проникає препарат у грудне молоко. Тому
застосування препарату для цієї</span><span lang=3DUK style=3D'font-family:=
"Times New Roman","serif"'>
</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Rom=
an","serif";
letter-spacing:-.05pt;mso-ansi-language:UK'>категорії пацієнтів не
рекомендується.</span><span style=3D'font-family:"Times New Roman","serif"'=
><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.3pt;mso-line-height-rule:exactly;background:white'><=
u><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
letter-spacing:-.15pt;mso-ansi-language:UK'>Кесарів розтин.</span></u><span
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:.7pt;margin-right:0cm;margin-botto=
m:0cm;
margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:13.3pt;
mso-line-height-rule:exactly;background:white'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:UK'>Застосув=
ання
Аркурону під час операції кесаревого розтину не змінює показники шкали</spa=
n><span
lang=3DUK style=3D'font-family:"Times New Roman","serif"'> </span><span lan=
g=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>Апгар, м'язовий тонус і кардіоваскулярну адаптацію новонародженого. Чер=
ез
плаценту</span><span lang=3DUK style=3D'font-family:"Times New Roman","seri=
f"'> </span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>проникає лише мінімальна кількість активної речовини
препарату і виявляється у крові</span><span lang=3DUK style=3D'font-family:=
"Times New Roman","serif"'>
</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Rom=
an","serif";
letter-spacing:-.2pt;mso-ansi-language:UK'>пуповини.</span><span
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:.35pt;margin-right:0cm;margin-bott=
om:0cm;
margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:13.3pt;
mso-line-height-rule:exactly;background:white'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:UK'>У вагітн=
их,
яким для лікування токсикозу застосовували солі магнію, що посилюють</span>=
<span
lang=3DUK style=3D'font-family:"Times New Roman","serif"'> </span><span lan=
g=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>нервово-м'язову блокаду, припинення міорелаксуючого ефекту медикаментоз=
ним
шляхом</span><span lang=3DUK style=3D'font-family:"Times New Roman","serif"=
'> </span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>може виявитися недостатнім. У таких випадках обов'язк=
ово слід
застосовувати стимулятор</span><span lang=3DUK style=3D'font-family:"Times =
New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";letter-spacing:-.05pt;mso-ansi-language:UK'>периф=
еричних
нервів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
i><span
lang=3DUK style=3D'font-size:8.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK;mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></i=
></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK;mso-bidi-font-weight:bold'>Здатність впливати на швидк=
ість
реакції при керуванні автотранспортом або іншими механізмами.</span></i><i
style=3D'mso-bidi-font-style:normal'><span style=3D'font-family:"Times New =
Roman","serif"'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>У перші 24 години після припинення міорелаксуючої дії
Аркурону не рекомендується керувати автомобілем або працювати з іншими
механізмами.</span><span style=3D'font-family:"Times New Roman","serif"'><o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:3.25pt;margin-bottom:.0001pt;text-align:justify;line-height:13.=
7pt;
mso-line-height-rule:exactly;tab-stops:15.5pt;background:white'><span
style=3D'font-size:8.0pt;font-family:"Times New Roman","serif"'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;background:white'><b><i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>Спосіб застосування та </span></i></b><b style=3D'mso-bidi-font-weight:=
normal'><i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>дози.</span></i></b><b style=3D'mso-bidi-font-weight:=
normal'><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:5.1pt;margin-bott=
om:0cm;
margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;
background:white'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Ti=
mes New Roman","serif";
mso-ansi-language:UK;mso-bidi-font-style:italic'>Як<i> </i></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>і у випадках з іншими нервово-м'язовими блокаторами, =
дозу
Аркурону слід підбирати для кожного пацієнта індивідуально, з урахуванням т=
ипу
анестезії, передбачуваної тривалості хірургічного втручання, можливих взаєм=
одій
з іншими лікарськими препаратами, які застосовуються до або під час анестез=
ії,
супутніх захворювань і загального стану хворого. Рекомендується застосовува=
ти
стимулятор периферичних нервів для забезпечення контролю нервово-м'язового
блоку.</span><span style=3D'font-family:"Times New Roman","serif"'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:5.1pt;margin-bott=
om:0cm;
margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;
background:white'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Ti=
mes New Roman","serif";
mso-ansi-language:UK'>Застосовувати препарат внутрішньовенно. Безпосередньо
перед введенням 4 мг сухої речовини препарату розчинити у 2 мл 0,9 % розчину
натрію хлориду.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:5.1pt;margin-bott=
om:0cm;
margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;
background:white'><u><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-ansi-language:UK'>Дорослим:</span></u><span lang=3DUK style=3D'font-fam=
ily:
"Times New Roman","serif";mso-ansi-language:UK'><o:p></o:p></span></p>

<p class=3DMsoListParagraphCxSpFirst style=3D'margin-top:0cm;margin-right:5=
.1pt;
margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;mso-add-space:auto;
text-align:justify;text-indent:3.15pt;mso-list:l1 level1 lfo4;background:wh=
ite'><![if !supportLists]><span
lang=3DUK style=3D'font-size:12.0pt;mso-bidi-font-size:10.0pt;mso-ansi-lang=
uage:
UK'><span style=3D'mso-list:Ignore'>–<span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><i><span lang=3DUK style=3D'font-size:12.0pt;
mso-ansi-language:UK'>початкова доза для інтубації і наступного хірургічного
втручання: </span></i><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-la=
nguage:
UK'>0,06-0,08 мг/кг <span style=3D'letter-spacing:-.05pt'>маси тіла, забезп=
ечує
умови для інтубації протягом 150-180 секунд, при цьому тривалість </span>м'=
язової
релаксації 60-90 хвилин;</span><span lang=3DUK style=3D'mso-ansi-language:U=
K'><o:p></o:p></span></p>

<p class=3DMsoListParagraphCxSpMiddle style=3D'margin-top:0cm;margin-right:=
5.1pt;
margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;mso-add-space:auto;
text-align:justify;text-indent:0cm;mso-list:l1 level1 lfo4;tab-stops:0cm;
background:white'><![if !supportLists]><span lang=3DUK style=3D'font-size:1=
2.0pt;
mso-ansi-language:UK'><span style=3D'mso-list:Ignore'>–<span style=3D'font:=
7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><i><span lang=3DUK style=3D'font-size:12.0pt;
mso-ansi-language:UK'>початкова доза для міорелаксацїї при інтубації з
використанням сукцинілхоліну:<br>
</span></i><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>=
0,05
мг/кг маси тіла, забезпечує 30-60-хвилинну міорелаксацію;<o:p></o:p></span>=
</p>

<p class=3DMsoListParagraphCxSpMiddle style=3D'margin-top:0cm;margin-right:=
5.1pt;
margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;mso-add-space:auto;
text-align:justify;text-indent:0cm;mso-list:l1 level1 lfo4'><![if !supportL=
ists]><span
lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'><span style=3D'ms=
o-list:
Ignore'>–<span style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><i><span lang=3DUK style=3D'font-size:12.0pt;
mso-ansi-language:UK'>підтримуюча доза: </span></i><span lang=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK'>0,01-0,02 мг/кг маси тіла,
забезпечує 30-60-хвилинну міорелаксацію під час хірургічної операції;<o:p><=
/o:p></span></p>

<p class=3DMsoListParagraphCxSpLast style=3D'margin-left:0cm;mso-add-space:=
auto;
text-indent:0cm;mso-list:l1 level1 lfo4;tab-stops:0cm;background:white'><![=
if !supportLists]><span
style=3D'font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style=3D'mso-lis=
t:Ignore'>–<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nb=
sp;
</span></span></span><![endif]><i><span lang=3DUK style=3D'font-size:12.0pt;
mso-ansi-language:UK'>пацієнтам з порушеннями функції нирок </span></i><span
lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>не рекомендується
застосовувати дози, що перевищують 0,04 мг/кг маси тіла.</span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><u><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";letter-spac=
ing:
-.4pt;mso-ansi-language:UK'>Дітям:</span></u><u><span style=3D'font-family:=
"Times New Roman","serif"'><o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>При комбінованому наркозі початкова доза Аркурону для дітей віком від 1=
 до
14 років</span><span lang=3DUK style=3D'font-family:"Times New Roman","seri=
f"'> </span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
letter-spacing:-.05pt;mso-ansi-language:UK'>становить 0,08-0,09 мг/кг.</spa=
n><span
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:.35pt;margin-right:0cm;margin-bott=
om:0cm;
margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;
tab-stops:0cm;background:white'><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>Новонародженим =
та
дітям до 1 року рекомендуються нижчі дози – 0,04-0,06 мг/кг.<o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>Зазначені дози препарату забезпечують релаксацію при 25-35-хвилинному
хірургічному</span><span lang=3DUK style=3D'font-family:"Times New Roman","=
serif"'>
</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Rom=
an","serif";
mso-ansi-language:UK'>втручанні. При необхідності подовження міорелаксації =
ще
на 25-35 хвилин препарат</span><span lang=3DUK style=3D'font-family:"Times =
New Roman","serif"'>
</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Rom=
an","serif";
mso-ansi-language:UK'>вводять повторно у дозі, що становить <sup>1</sup>/<s=
ub>3</sub>
від початкової дози.</span><span style=3D'font-family:"Times New Roman","se=
rif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><u><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>Можливе подовження часу дії препарату у наступних випадках:</span></u><=
span
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoListParagraphCxSpFirst style=3D'margin-top:.35pt;margin-right=
:0cm;
margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;mso-add-space:auto;
text-align:justify;text-indent:0cm;mso-list:l1 level1 lfo4;tab-stops:0cm 10=
.45pt;
background:white'><![if !supportLists]><span lang=3DUK style=3D'font-size:1=
2.0pt;
mso-ansi-language:UK'><span style=3D'mso-list:Ignore'>–<span style=3D'font:=
7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
mso-ansi-language:UK'>надлишкова маса тіла, ожиріння (при підборі дози слід
виходити з ідеальної маси тіла);<o:p></o:p></span></p>

<p class=3DMsoListParagraphCxSpMiddle style=3D'margin-top:.7pt;margin-right=
:0cm;
margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;mso-add-space:auto;
text-align:justify;text-indent:0cm;mso-list:l1 level1 lfo4;tab-stops:0cm 10=
.45pt;
background:white'><![if !supportLists]><span lang=3DUK style=3D'font-size:1=
2.0pt;
mso-ansi-language:UK'><span style=3D'mso-list:Ignore'>–<span style=3D'font:=
7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
mso-ansi-language:UK'>одночасне застосування інгаляційних анестетиків (дозу
Аркурону можна зменшити);<o:p></o:p></span></p>

<p class=3DMsoListParagraphCxSpLast style=3D'margin-top:1.1pt;margin-right:=
0cm;
margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;mso-add-space:auto;
text-align:justify;text-indent:0cm;mso-list:l1 level1 lfo4;tab-stops:0cm 10=
.45pt;
background:white'><![if !supportLists]><span lang=3DUK style=3D'font-size:1=
2.0pt;
mso-ansi-language:UK'><span style=3D'mso-list:Ignore'>–<span style=3D'font:=
7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
mso-ansi-language:UK'>під час інтубації із сукцинілхоліном (Аркурон вводити
після зникнення клінічних ознак дії сукцинілхоліну. Як і у випадку з іншими
недеполяризуючими міорелаксантами, введення Аркурону після деполяризуючого
міорелаксанту може скоротити час, необхідний для настання міорелаксації, і
збільшити тривалість максимального ефекту). <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:1.1pt;margin-right:0cm;margin-bott=
om:0cm;
margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;
tab-stops:0cm 10.45pt;background:white'><u><span lang=3DUK style=3D'font-si=
ze:12.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>Припинення ефек=
ту:</span></u><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'> при 80-85&nbsp;% блокаді, виміряної за допомогою
стимулятора периферичних нервових волокон, або при частковій блокаді,
визначеній за клінічними <span style=3D'letter-spacing:-.05pt'>ознаками,
застосування атропіну (дорослим у дозі 0,5-1,25 мг) у комбінації з неостигм=
іном
</span>(дорослим у дозі 1-3 мг) або галантаміном (дорослим у дозі 10-30 мг)
припиняє міорелаксуючу дію Аркурону.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;background:white'><i><span lang=3DUK style=3D'font-size:8.0pt;line-=
height:
115%;font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p>&nbsp=
;</o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;background:white'><i><span lang=3DUK style=3D'font-size:12.0pt;line=
-height:
115%;font-family:"Times New Roman","serif";mso-ansi-language:UK'>Діти.</spa=
n></i><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-family:"=
Times New Roman","serif";
mso-ansi-language:UK'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;background:white'><span lang=3DUK style=3D'font-size:12.0pt;line-he=
ight:
115%;font-family:"Times New Roman","serif";mso-ansi-language:UK'>Препарат
застосовувати дітям від народження (див. розділ «Спосіб застосування та доз=
и»).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt'><b
style=3D'mso-bidi-font-weight:normal'><i><span lang=3DUK style=3D'font-size=
:8.0pt;
line-height:115%;font-family:"Times New Roman","serif";mso-ansi-language:UK=
'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><b style=3D'mso-=
bidi-font-weight:
normal'><i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New=
 Roman","serif";
mso-ansi-language:UK'>Передозування.</span></i></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></=
span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm'><span lang=3DUK style=3D'font-siz=
e:12.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>У випадку
передозування або тривалої нервово-м'язової блокади штучну вентиляцію леген=
ів
продовжувати до відновлення спонтанного дихання. На початку відновлення
спонтанного дихання як антидот вводити інгібітор ацетилхолінестерази (напри=
клад
неостигмін, піридостигмін, едрофоній) у відповідній дозі. До відновлення
задовільного спонтанного дихання слід проводити ретельний контроль дихальної
функції.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm'><span lang=3DUK style=3D'font-siz=
e:8.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p>&nbsp;</o:=
p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><b style=3D'mso-=
bidi-font-weight:
normal'><i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New=
 Roman","serif";
mso-ansi-language:UK'>Побічні реакції.</span></i></b><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-=
ansi-language:
UK'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>Найчастішим побічним ефектом недеполяризуючих блокаторів як класу є
подовження</span><span lang=3DUK style=3D'font-family:"Times New Roman","se=
rif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>фармакологічної дії довше
періоду часу, необхідного для хірургічного втручання та</span><span lang=3D=
UK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'> </spa=
n><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>анестезії. Клінічні прояви можуть варіювати від слабк=
ості
скелетних м'язів до глибокого</span><span lang=3DUK style=3D'font-family:"T=
imes New Roman","serif";
mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-ansi-language:UK'>та тривалого паралічу скеле=
тних
м'язів, що може призвести до дихальної недостатності</span><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'> </spa=
n><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
letter-spacing:-.25pt;mso-ansi-language:UK'>або апное.</span><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><i><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>З боку судин: </span></i><span lang=3DUK style=3D'font-size:12.0pt;font=
-family:
"Times New Roman","serif";mso-ansi-language:UK'>артеріальна гіпотензія,
артеріальна гіпертензія, інсульт, тромбоз, вазоділатація.</span><span lang=
=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:.35pt;margin-right:0cm;margin-bott=
om:0cm;
margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;
tab-stops:0cm;background:white'><i><span lang=3DUK style=3D'font-size:12.0p=
t;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>З боку серця: <=
/span></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK;mso-bidi-font-style:italic'>аритмія, </span><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>брадикардія, пригнічення роботи серця, тахікардія і фібриляція шлуночкі=
в, ішемія
міокарда, фібриляція передсердь, шлуночкова</span><span lang=3DUK
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:UK'> </spa=
n><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
letter-spacing:-.15pt;mso-ansi-language:UK'>екстрасистолія.</span><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><i><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>З боку обміну речовин та харчування: </span></i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>підвищення рівня креатиніну, гіпоглікемія, гіперкаліємія, тетанія.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><i style=3D'mso-=
bidi-font-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man","serif";
mso-ansi-language:UK'>Психічні розлади:</span></i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'> сонливість.</span><span lang=3DUK style=3D'font-family:"Times New Roma=
n","serif";
mso-ansi-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><i><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>З боку кістково-м’язової системи та сполучної тканини: </span></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>м'язова атрофія,</span><span lang=3DUK style=3D'font-=
family:
"Times New Roman","serif";mso-ansi-language:UK'> </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";letter-spac=
ing:
-.05pt;mso-ansi-language:UK'>утруднена інтубація, м’язова слабкість.</span>=
<span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><i><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";letter-spac=
ing:
-.05pt;mso-ansi-language:UK'>З боку нервової системи: </span></i><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";letter-spac=
ing:
-.05pt;mso-ansi-language:UK'>гіпестезія, пригнічення центральної нервової</=
span><span
lang=3DUK style=3D'font-family:"Times New Roman","serif"'> </span><span lan=
g=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";letter-spac=
ing:
-.25pt;mso-ansi-language:UK'>системи, параліч.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><i style=3D'mso-=
bidi-font-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man","serif";
letter-spacing:-.25pt;mso-ansi-language:UK'>З боку органів зору: </span></i=
><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
letter-spacing:-.25pt;mso-ansi-language:UK'>блефарит.</span><span
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><i><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>З боку дихальної системи, органів грудної клітки та середостіння: </spa=
n></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK;mso-bidi-font-style:italic'>апное,<i> </i></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>диспное</span><span style=3D'font-size:12.0pt;font-fa=
mily:
"Times New Roman","serif"'> (</span><span lang=3DUK style=3D'font-size:12.0=
pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>задишка</span><=
span
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif"'>)</span><s=
pan
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>, пригнічення дихання, гіповентиляція легенів,
бронхоспазм, ларингоспазм, ателектаз, кашель.</span><span style=3D'font-fam=
ily:
"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><i><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>З боку шкіри і підшкірних тканин: </span></i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>висипання, кропив'янка.</span><span style=3D'font-family:"Times New Rom=
an","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><i><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>З боку нирок та сечовивідної системи: </span></i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>анурія.</span><span style=3D'font-family:"Times New Roman","serif"'><o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><i><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>З боку імунної системи: </span></i><span lang=3DUK style=3D'font-size:1=
2.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>алергічні реакц=
ії;
у поодиноких випадках – анафілактичні та</span><span lang=3DUK style=3D'fon=
t-family:
"Times New Roman","serif"'> </span><span lang=3DUK style=3D'font-size:12.0p=
t;
font-family:"Times New Roman","serif";letter-spacing:-.05pt;mso-ansi-langua=
ge:
UK'>анафілактоїдні реакції.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><i style=3D'mso-=
bidi-font-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man","serif";
mso-ansi-language:UK'>З боку лабораторних показників:</span></i><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'> незначне зниження рівня калію, магнію, кальцію у плазмі крові; підвище=
ння
рівня глюкози; збільшення концентрації сечовини у крові; зменшення частоти
серцевих скорочень.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm;background:white'><span lang=3DUK
style=3D'font-size:8.0pt;font-family:"Times New Roman","serif";mso-ansi-lan=
guage:
UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;background:white'><b><i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>Термін придатності. </span></i></b><span lang=3DUK style=3D'font-size:1=
2.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK;mso-bidi-font-st=
yle:
italic'>2<i> </i></span><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-ansi-language:UK'>роки.</span><span style=3D'font-family:"Times New Rom=
an","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
b><span
lang=3DUK style=3D'font-size:8.0pt;font-family:"Times New Roman","serif";
letter-spacing:-.05pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;background:white'><b><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman","serif";letter-spacing:-.05pt;mso-ansi=
-language:
UK'>Умови зберігання.</span></b><span style=3D'font-family:"Times New Roman=
","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;background:white'><span lang=3DUK style=3D'font-=
size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:UK'>Зберігат=
и у
захищеному від світла місці при температурі від 2&nbsp;°С до 8</span><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-ansi-language:=
UK'>&nbsp;</span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:UK'>°С. Зберігати у недоступному для дітей місці.<o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;background:white'><span lang=3DUK style=3D'font-=
size:
8.0pt;font-family:"Times New Roman","serif";mso-ansi-language:UK'><o:p>&nbs=
p;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;background:white'><b style=3D'mso-bidi-font-weig=
ht:
normal'><i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New=
 Roman","serif";
letter-spacing:-.4pt;mso-ansi-language:UK'>Несумісні<span style=3D'mso-bidi=
-font-weight:
bold'>сть.</span></span></i></b><span style=3D'font-family:"Times New Roman=
","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;background:white'><span lang=3DUK style=3D'font-=
size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:UK'>Аркурон =
не
слід змішувати з іншими інфузійними розчинами в одній ємкості.</span><span
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:13.7pt;mso-line-height-rule:exactly;background:white'><=
span
style=3D'font-size:8.0pt;font-family:"Times New Roman","serif"'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;background:white'><b><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman","serif";letter-spacing:-.2pt;mso-ansi-=
language:
UK'>Упаковка.</span></b><b><span lang=3DUK style=3D'font-size:12.0pt;font-f=
amily:
"Times New Roman","serif";letter-spacing:-.2pt'> </span></b><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>По 4 мг в ампулах № 10.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;background:white'><span style=3D'font-size:8.0pt;
font-family:"Times New Roman","serif"'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;background:white'><b><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:UK'>Категорія
відпуску. </span></b><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-ansi-language:UK'>За рецептом.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;background:white'><span style=3D'font-size:8.0pt;
font-family:"Times New Roman","serif"'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm 14.2pt 57.75pt'><b style=3D'mso-bi=
di-font-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man","serif";
mso-fareast-font-family:Calibri;mso-ansi-language:UK;mso-fareast-language:E=
N-US'>Виробник.</span></b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:Calibri;mso-ansi-language:UK;mso-fareast-language:E=
N-US'>
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm 14.2pt 57.75pt'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";background:=
white;
mso-ansi-language:UK'>ТОВ «БІОЛІК ФАРМА».<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm 14.2pt 57.75pt'><span lang=3DUK
style=3D'font-size:8.0pt;font-family:"Times New Roman","serif";mso-fareast-=
font-family:
Calibri;mso-ansi-language:UK;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm 14.2pt 57.75pt'><b style=3D'mso-bi=
di-font-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man","serif";
mso-fareast-font-family:Calibri;mso-ansi-language:UK;mso-fareast-language:E=
N-US'>Місцезнаходження
виробника та адреса місця провадження його діяльності.</span></b><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
Calibri;mso-ansi-language:UK;mso-fareast-language:EN-US'> <o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.7pt;margin-bottom:.0001pt;line-height:normal;mso-pagination:no=
ne;
background:white;mso-layout-grid-align:none;text-autospace:none'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>Місцезнаходження
юридичної особи: <o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.7pt;margin-bottom:.0001pt;line-height:normal;mso-pagination:no=
ne;
background:white;mso-layout-grid-align:none;text-autospace:none'><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>Україна, 61070, Харківська обл., місто Харків, Помірки, будинок 70. <o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.7pt;margin-bottom:.0001pt;line-height:normal;mso-pagination:no=
ne;
background:white;mso-layout-grid-align:none;text-autospace:none'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-ansi-language:UK'>Адреса місця
провадження діяльності: <o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.7pt;margin-bottom:.0001pt;line-height:normal;mso-pagination:no=
ne;
background:white;mso-layout-grid-align:none;text-autospace:none'><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>Україна, 61070, Харківська обл., місто Харків, Помірки-70, будинок б/н.=
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:0cm'><b><span style=3D'font-size:8.0pt;
font-family:"Times New Roman","serif"'><o:p>&nbsp;</o:p></span></b></p>

</div>

</body>

</html>

------=_NextPart_01DA5860.84644740
Content-Location: file:///C:/680C1E39/UA61760101_6F09.files/preview.wmf
Content-Transfer-Encoding: base64
Content-Type: image/x-wmf
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==

------=_NextPart_01DA5860.84644740
Content-Location: file:///C:/680C1E39/UA61760101_6F09.files/item0001.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<b:Sources SelectedStyle=3D"\APA.XSL" StyleName=3D"APA" xmlns:b=3D"http://s=
chemas.openxmlformats.org/officeDocument/2006/bibliography" xmlns=3D"http:/=
/schemas.openxmlformats.org/officeDocument/2006/bibliography"></b:Sources>

------=_NextPart_01DA5860.84644740
Content-Location: file:///C:/680C1E39/UA61760101_6F09.files/props002.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<ds:datastoreItem ds:itemID=3D"{8E86782B-E465-433C-9153-482F52C5AABA}" xmln=
s:ds=3D"http://schemas.openxmlformats.org/officeDocument/2006/customXml"><d=
s:schemaRefs><ds:schemaRef ds:uri=3D"http://schemas.openxmlformats.org/offi=
ceDocument/2006/bibliography"/></ds:schemaRefs></ds:datastoreItem>
------=_NextPart_01DA5860.84644740
Content-Location: file:///C:/680C1E39/UA61760101_6F09.files/themedata.thmx
Content-Transfer-Encoding: base64
Content-Type: application/vnd.ms-officetheme
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------=_NextPart_01DA5860.84644740
Content-Location: file:///C:/680C1E39/UA61760101_6F09.files/colorschememapping.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"yes"?>
<a:clrMap xmlns:a=3D"http://schemas.openxmlformats.org/drawingml/2006/main"=
 bg1=3D"lt1" tx1=3D"dk1" bg2=3D"lt2" tx2=3D"dk2" accent1=3D"accent1" accent=
2=3D"accent2" accent3=3D"accent3" accent4=3D"accent4" accent5=3D"accent5" a=
ccent6=3D"accent6" hlink=3D"hlink" folHlink=3D"folHlink"/>
------=_NextPart_01DA5860.84644740
Content-Location: file:///C:/680C1E39/UA61760101_6F09.files/header.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link id=3DMain-File rel=3DMain-File href=3D"../UA61760101_6F09.htm">
<![if IE]>
<base href=3D"file:///C:\680C1E39\UA61760101_6F09.files\header.htm"
id=3D"webarch_temp_base_tag">
<![endif]>
</head>

<body lang=3DRU>

<div style=3D'mso-element:footnote-separator' id=3Dfs>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span style=3D'mso-special-character:footnote-separator'><![if !sup=
portFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></p>

</div>

<div style=3D'mso-element:footnote-continuation-separator' id=3Dfcs>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span style=3D'mso-special-character:footnote-continuation-separato=
r'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></p>

</div>

<div style=3D'mso-element:endnote-separator' id=3Des>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span style=3D'mso-special-character:footnote-separator'><![if !sup=
portFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></p>

</div>

<div style=3D'mso-element:endnote-continuation-separator' id=3Decs>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span style=3D'mso-special-character:footnote-continuation-separato=
r'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></p>

</div>

<div style=3D'mso-element:footer' id=3Df1>

<p class=3DMsoFooter align=3Dright style=3D'text-align:right'><!--[if suppo=
rtFields]><span
style=3D'font-family:"Times New Roman","serif"'><span style=3D'mso-element:=
field-begin'></span>PAGE<span
style=3D'mso-spacerun:yes'>   </span>\* MERGEFORMAT<span style=3D'mso-eleme=
nt:field-separator'></span></span><![endif]--><span
style=3D'font-family:"Times New Roman","serif"'><span style=3D'mso-no-proof=
:yes'>5</span></span><!--[if supportFields]><span
style=3D'font-family:"Times New Roman","serif"'><span style=3D'mso-element:=
field-end'></span></span><![endif]--></p>

<p class=3DMsoFooter><o:p>&nbsp;</o:p></p>

</div>

</body>

</html>

------=_NextPart_01DA5860.84644740
Content-Location: file:///C:/680C1E39/UA61760101_6F09.files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../UA61760101_6F09.htm"/>
 <o:File HRef=3D"preview.wmf"/>
 <o:File HRef=3D"item0001.xml"/>
 <o:File HRef=3D"props002.xml"/>
 <o:File HRef=3D"themedata.thmx"/>
 <o:File HRef=3D"colorschememapping.xml"/>
 <o:File HRef=3D"header.htm"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01DA5860.84644740--
